Applied Filters
Bio-Techne takes patent dispute to UK
The lawsuit centres on patented molecular instruments | The patents-in-suit cover cover features of RNAscope tech.
EMA backs switch to biosimilars
Evidence shows medicines approved as biosimilars in the EU may be prescribed interchangeably | Additional ‘switch’ studies no longer not need to be carried out.
Swiss watchdog investigates Novartis over patent use
Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition
Microsoft partners with Nordic data science firm on AI project
Deal set to enable faster use of artificial intelligence in drug discovery | Planned AI models to identify novel targets and establish biomarkers of disease.
Big pharma firm hits back in COVID-19 tech dispute
CureVac accuses Pfizer and its German partner of infringing patented tech in landmark COVID-19 treatment | The pharma giant says that the patents are invalid
Novo Nordisk makes $1.1bn bid for biopharma company
Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Carpmaels & Ransford adds partner with UPC focus
New partner brings pharma and chemistry focus, and boosts the European firm’s Unified Patent Court team.
UK pharma firm ‘stole’ psilocybin secrets from professor
Mental health specialists in dispute over psilocybin | Terran Biosciences accuses Compass Pathways of ‘milking’ professor before ‘secretly’ filing a patent for the medicine.
Competition watchdog fines big pharma duo £70m
The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.
Bad news for Italy’s EMA relocation challenge
EU’s top court denies bid that Amsterdam decision was a “misuse of powers” | Complaint said The Netherlands facility wasn’t ready | Milan lost out after random pick from a fish bowl.
